ADMA Biologics, Inc. (NASDAQ: ADMA) is a Healthcare company (Biotechnology) with a market capitalization of $3.0B. The Maz Rating grades it against the other companies in its sector.
ADMA Biologics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $13.63, ADMA Biologics, Inc. trades at 17.1x trailing earnings, 5.8x sales and 6.9x book value, with an EV/EBITDA of 12.3. Over the last twelve months it generated about $525M of revenue and $177M of net income. It runs a gross margin of 68.5%, an operating margin of 44.9% and a net margin of 35.1%. It shows return on equity of 42.6%, return on invested capital of 28.2% and a free cash flow yield of 4.4%. On the balance sheet: a debt-to-equity ratio of 0.46 and a current ratio of 6.04. Over the past 52 weeks the share price ranged from $7.21 to $20.46, with a beta of 0.77.
ADMA Biologics, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 1 Strong Buy, 8 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, ADMA Biologics, Inc. (ADMA) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 8.25% / 30% · (Cash+Inv) / Mkt Cap (36m) 5.24% / 30% · Interest income / Revenue 0.92% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 8.25% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.24% / 33% · Receivables / Mkt Cap (36m) 7.12% / 49% · Interest income / Revenue 0.92% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 8.25% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.24% / 33.33% · Receivables / Mkt Cap (24m) 7.12% / 33.33% · Interest income / Revenue 0.92% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 24.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 18.0% / 33.33% · Receivables / Avg Assets (4Q) 22.2% / 33.33% · Interest income / Revenue 0.92% / 5% | Pass |
| FTSE | Debt / Total Assets 26.7% / 33.33% · (Cash+ST Inv) / Total Assets 17.0% / 33.33% · (Cash+Recv) / Total Assets 40.1% / 33.33% · Interest income / Revenue 0.92% / 5% | Fail |
It depends on the standard you follow. As of September 2026, ADMA Biologics, Inc. (ADMA) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. ADMA Biologics, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.92% of each dividend: ADMA Biologics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.